The antibiotic azithromycin is a motilin receptor agonist in human stomach: Comparison with erythromycin

British Journal of Pharmacology

Volumn 168, Issue 8, 2013, Pages 1859-1867

  Broad, John ^a   Sanger, Gareth J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

azithromycin; erythromycin; human; motilin; stomach

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN LACTOBIONATE; HORMONE RECEPTOR; IODINE 125; MOTILIN; MOTILIN RECEPTOR; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CALCIUM; GASTROINTESTINAL AGENT; NEUROPEPTIDE RECEPTOR; RECOMBINANT PROTEIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CHOLINERGIC ACTIVITY; CHOLINERGIC STIMULATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ELECTROSTIMULATION; FACILITATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUSCLE TONE; NITRERGIC NERVE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SMOOTH MUSCLE CONTRACTION; STOMACH EMPTYING; STOMACH MUSCLE; AGONISTS; ANIMAL; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY; STOMACH ANTRUM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CALCIUM; CHO CELLS; CRICETULUS; ELECTRIC STIMULATION; ERYTHROMYCIN; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MIDDLE AGED; MOTILIN; OBESITY; PYLORIC ANTRUM; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE; RECOMBINANT PROTEINS;

EID: 84875465813     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12077     Document Type: Article

References (35)

1. Abrahamsson H, (2007). Treatment options for patients with severe gastroparesis. Gut 56: 877-883.
2. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F, (2004). Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacol Res 50: 211-222.
3. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ, (2012). Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 167: 763-774.
5. Chen CY, Tsai CY, (2012). Ghrelin and motilin in the gastrointestinal system. Curr Pharm Des 18: 4755-4765.
6. Chini P, Toskes PP, Waseem S, Hou W, McDonald R, Moshiree B, (2012). Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol 47: 422-427.
7. Chiragh S, Begum A, Karim S, (2006). Prokinetic effect of clarithromycin and azithromycin-in vitro study on rabbit duodenum. Biomedica 22: 130-134.
8. Coulie B, Tack J, Peeters T, Janssens J, (1998). Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 43: 395-400.
9. Dass NB, Hill J, Muir A, Testa T, Wise A, Sanger GJ, (2003). The rabbit motilin receptor: molecular characterisation and pharmacology. Br J Pharmacol 140: 948-954.
10. Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong S-S, et al. (1999). Receptor for motilin identified in the human gastrointestinal system. Science 284: 2184-2188.
11. Furness JB, Clark MJ, Wright T, Bertrand PP, Bornstein JC, Verlinden M, (1999). An action of erythromycin in the intestine that is not mediated via motilin receptors. Clin Exp Pharmacol Physiol 26: 100-104.
12. Hawkyard CV, Koerner RJ, (2007). The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother 59: 347-358.
13. Hopkins S, (1991). Clinical toleration and safety of azithromycin. Am J Med 91: 40S-45S.
14. Jarvie EM, North-Laidler V, Corcoran S, Bassil A, Sanger GJ, (2007). Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro. Br J Pharmacol 150: 455-462.
15. Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B, (2010). Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil 16: 407-413.
16. Mertens V, Blondeau K, Pauwels A, Farre R, Vanaudenaerde B, Vos R, et al. (2009). Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci 54: 972-979.
17. Miller P, Roy AS, Pierre S, Dagenais M, Lapointe R, Poitras P, (2000). Motilin receptors in the human antrum. Am J Physiol Gastrointest Liver Physiol 278: G18-G23.
18. Moshiree B, McDonald R, Hou W, Toskes PP, (2010). Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 55: 675-683.
19. Omura S, (2002). Macrolide Antibiotics: Chemistry, Biology and Practice, 2nd edn. Academic Press: San Diego, CA.
20. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G, (1989). Erythromycin is a motilin receptor agonist. Am J Physiol 257: G470-G474.
21. Ray WA, Murray KT Meredith S, Narasimhulu SS, Hall K, Stein CM, (2004). Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351: 1089-1096.
22. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM, (2012). Azithromycin and the risk of cardiovascular death. N Engl J Med 366: 1881-1890.
23. Rohof WO, Bennink RJ, Ruigh AA, Hirsch DP, Zwinderman AH, Boeckxstaens GE, (2012). Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 61: 1670-1677.
24. Sanger GJ, (2008). Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. Drug Discov Today 13: 234-239.
25. Sanger GJ, Alpers D, (2008). Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 20: 177-184.
26. Sanger GJ, Westaway SM, Barnes AA, MacPherson DT, Muir AI, Jarvie EM, et al. (2009). GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 21: 657-666. et al.
27. Sanger GJ, Wang Y, Hobson A, Broad J, (2012). Motilin: toward a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol DOI: 10.1111/bph.12075.
28. Sifrim D, Matsuo H, Janssens J, Vantrappen G, (1994). Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res 20: 121-126.
29. Thielemans L, Depoortere I, Perret J, Robberecht P, Liu Y, Thijs T, et al. (2005). Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther 313: 1397-1405.
30. Van Assche G, Depoortere I, Thijs T, Janssens JJ, Peeters TL, (1997). Concentration-dependent stimulation of cholinergic motor nerves or smooth muscle by [Nle13]motilin in the isolated rabbit gastric antrum. Eur J Pharmacol 337: 267-274.
31. Vrančic̈ M, Banjanac M, Nujic̈ K, Bosnar M, Murati T, Munic̈ V, et al. (2012). Azithromycin distinctively modulates classical activation of human monocytes in vitro. Br J Pharmacol 165: 1348-1360.
32. Westaway SM, Sanger GJ, (2009). The identification and rationale for drugs which act at the motilin receptor. Prog Med Chem 48: 31-80.
33. Wildfeuer A, Laufen H, Zimmermann T, (1994). Distribution of orally administered azithromycin in various blood compartments. Int J Clin Pharmacol Ther 32: 356-360.
34. Zhao DM, Xue HH, Chida K, Suda T, Oki Y, Kanai M, et al. (2000). Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol 278: L726-L736.
35. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, et al. (2004). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5: 415-442.